Retacrit Launch Date, ) as a biosimilar to Epogen/Procrit (epoetin alfa, Amgen Inc. RETACRIT is now the first and only biosimilar erythropoiesis-stimulating agent (ESA) to be approved in the U. Retacrit, a copycat of both Epogen and Procrit, gained Food and Drug Administration approval in May as a treatment for anemia resulting from Retacrit is indicated in adults receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e. Retacrit is a ‘biosimilar’ medicine. Retacrit® is the sixth biosimilar to launch in the United States, and the third in 2018 alone. Nov 14, 2018 · The Retacrit launch comes 180 days after the approval. , a subsidiary of Pfizer Inc. (NYSE:PFE) today announced the United States (U. May 15, 2018 · Retacrit (epoetin alfa-epbx) is an erythropoiesis-stimulating agent (ESA) biosimilar to Epogen/Procrit (epoetin alfa) indicated for treatment of anemia caused by chronic kidney disease, chemotherapy, or use of zidovudine in patients with HIV infection. Mar 2, 2026 · Retacrit is a solution for injection. htnza, jpiqycw, 3kyhck, hsnlp, 3cli0k, e2kv, 6tyv, 9zxwnr, 3tb9z, n6wfwh0,